Dr. Brad Cox, a fermentation expert who has helped develop F3’s capabilities, will lead the Euglena project at Algatech and support its fermentation activity.
The new technology, developed under the product name BioGlena, derives Beta-1,3-glucans from fermented Euglena. The company says that while the beta glucans are currently available from sources including yeast, oats, and mushrooms, they are more concentrated and purer when derived from Euglena, due to their chemical structure and processing techniques. BioGlena is said to be more efficient and to produce a higher-quality ingredient than previously possible.
Related: Solabia Group Acquires Algatech For The Biome Partners with Algatech New Ingredient: AstraPure-EyeQ
Algatech intends to launch several products using the algae-derived beta glucan, which will expand Algatech’s existing product offering and support its mission to develop commercial, microalgae-based products.
Hagai Stadler, CEO of Algatech, said in the release: “Currently only a tiny fraction of the world’s microalgae has been developed for commercial use, despite the vast potential these organisms can have in tackling societal health issues. Beta-1,3-glucans act as immunomodulators and prime immune cells—we are excited to explore new and innovative ways to deliver on Algatech’s mission to unlock the power and health benefits of microalgae for consumers. We expect to launch the first Euglena-based product in the coming months.”
Jonathan Peskoff, COO of F3 Platform Biologics, said: “After years of development, we are happy to have found a home for our cutting-edge technology. Algatech’s cultivation and marketing capabilities will allow this technology to prosper and will ensure that its benefits are realized by customers around the world. We are proud of the team’s achievements, especially the head of the project, Dr. Brad Cox, who will lead fermentation technology at Algatech.”
